[mRS] score, 0-2).
I
ntravenous thrombolysis (IVT) with alteplase is the only approved clot-busting medical therapy in acute ischemic stroke, yet approximately half of the patients treated achieve recanalization in acute setting. 1 Regarding functional benefit, a similar percentage of patients achieve good outcome (independence in activities of daily life; modified Rankin scale prognostic tool, the DRAGON score, that was derived in the Helsinki cohort (n=1319) and validated in the Basel cohort (n=333). 4 It consists of parameters that are available soon after patient admission-before IVT administration ( Table 1) . The score was developed for ultraearly estimation of patient prognosis. It reliably identifies patients who will very likely benefit from IVT but also those with high likelihood of miserable outcome, despite IVT. In the latter group, an invasive endovascular procedure 5, 6 can be an alternative treatment of choice, although currently that is not evidence-based. Such an approach is an alternative in some centers in situations in which severe symptoms persist, despite thrombolytic treatment, as a rescue strategy. 7, 8 The DRAGON score showed very good performance in the original derivation and validation cohorts: area under the receiver operating characteristic curve (AUC-ROC) 0.84 (0.80-0.87) and 0.80 (0.74-0.86), respectively. 4 Furthermore, the DRAGON score was recently adapted for patients undergoing MRI instead of CT as the first-line imaging modality, 9 reporting performance similar to that in the original publication. In this study, we validated the DRAGON score in a large multicenter cohort to address its generalizability. We also tested the score separately in anterior and posterior circulation and in women and men.
Patients and Methods

Study Setting
The study includes data from 12 European and Australian stroke centers and was approved by the relevant authorities in each participating center, if required. This study was approved in the coordinating center (Helsinki) as a quality registry and did not require ethical board review. All patients were prospectively included in the database. Data from individual consecutive patients receiving IVT for acute ischemic stroke (without subsequent endovascular procedure) were collected with a standardized form with predefined variables. Local study investigators completed the forms systematically using prospectively ascertained in-hospital thrombolysis registries. Completed forms from all centers were compiled in the coordinating center (Helsinki), where the analyses of the pooled data (n=5471) were performed. We only considered patients with information available for all necessary baseline parameters, some of which were missing for 820 patients (footnote of Table 2), leaving 4519 eligible patients. None of the patients from the original derivation cohort 4 was included in the current analysis. The merged validation cohort comprises patients with both anterior and posterior circulation strokes. CT scans were evaluated by the local investigators, who were blinded to the results of CT angiography (if performed). Early infarct signs refer to an observation of any of the following: hypodensity in any cerebral artery territory, loss of basal ganglion outline, loss of insular ribbon, or effacement of sulci.
Statistical Analyses
The derivation of the DRAGON score (Table 1) is described in the original publication. 4 Discrimination statistics (AUC-ROC) tested the performance of the score for good (mRS score, 0-2) and miserable (mRS score, 5-6) outcomes. Two prespecified subgroup analyses were performed: AUC-ROC in anterior versus posterior circulation strokes and in women versus men. Positive and negative likelihood ratios, positive and negative predictive values, and their 95% confidence intervals were calculated for different cut-off values of the score. Calibration of the model was tested with the Hosmer-Lemeshow test. Analyses were performed on IBM SPSS 18 (IBM Corp, Armonk, NY).
Results
The demographics and baseline characteristics of patients included in the merged cohort (n=4519) are presented in Table I in Proportions of patients with miserable outcomes (mRS score, 5-6) were 0%, 2%, 4%, 89%, and 97% for 0 to 1, 2, 3, 8, and 9 to 10 points, respectively. For mRS score 5 to 6 and DRAGON score 9 to 10, positive likelihood ratio was 45.4 (13.9-147.6), negative likelihood ratio was 1.0 (0.9-1.0), positive predictive value was 91.7% (77.5-98.2), negative predictive value was 81.1% (79.9-82.2), specificity was 99.9% (99.8-100), and sensitivity was 3.7% (2.6-5.2). In case of DRAGON score 8 to 10, the corresponding numbers were as follows: positive likelihood ratio was 24.9 (16.3-38.1), negative likelihood ratio was 0.8 (0.8-0.9), positive predictive value was 85.8% (79.6-90.7), negative predictive value was 83.1% (81.9-84.2), specificity was 99.3% (99.0-99.6), and sensitivity was 16.4 (14.1-19.1).
Proportions of patients with good outcome (mRS score, 0-2) were 96%, 93%, 78%, and 0% for 0 to 1, 2, 3, and 8 to 10 score points, respectively. For mRS score 0 to 2 and DRAGON score 0 to 2, positive likelihood ratio was 8.3 (6.6-10.5), negative likelihood ratio was 0.7 (0.7-0.7), positive predictive value was 91.5% (89.4-93.3), negative predictive value was 51.8% (50.2-53.4), specificity was 96.4 (95.4-97.1), and sensitivity was 30.3 (28.5-32.1).
Discussion
In a large multicenter cohort of 4519 patients, we successfully validated the DRAGON score, which accurately predicts outcome of IVT-treated ischemic stroke patients. Performance of the score was similarly good (AUC-ROC=0.85) in the original derivation cohort 4 and in the multicenter-merged cohort (Figure 2) . Baseline characteristics were similar between original derivation 4 cohort and the current merged cohort ( Table 2 ). Advantages of the DRAGON score are manifold: (1) it is simple, (2) does not require any computer calculations, (3) consists of parameters that are available immediately after patient admission, (4) is very fast to calculate, and (5) is cost-free. In this multicenter study, we improved the generalizability of the DRAGON score by validating it in patients with both anterior and posterior circulation ischemic strokes and in women and men separately.
The score estimates which patients have a very high likelihood of miserable outcome (bedridden incontinent patient in institutional care or death; mRS score, 5 and 6, respectively), despite administration of the only approved recanalization treatment for acute ischemic stroke, IVT with alteplase. Such patients are, in some centers, offered rescue add-on therapy (eg, endovascular procedure). These procedures are, however, not currently evidence-based. In case the use of such add-on rescue strategies is in line with local institutional protocols, the clinicians must act promptly to not lose time. 10 In such situations, rapid arrangements of the endovascular procedures can be based on the DRAGON score, which is calculated even before IVT administration.
Based on the performance of the DRAGON score in the derivation and validation cohorts, patients with scores 0 to 3 have very high likelihood for good recovery after IVT. For patients with scores 7 to 10, the chances for good recovery are very Figure 1 . Three-month outcome per increasing points in the DRAGON score in the merged cohort (n=4519). Good 3-month outcome (gray bars), modified Rankin scale (mRS) score 0 to 2, indicates independence in activities of daily living. Miserable outcome (black bars) corresponds to being bedridden, incontinent, and requiring constant nursing care and attention (mRS score, 5) or dead (mRS score, 6). Note that for better clarity, mRS score 3 to 4 is not in the chart. low. In institutions where rescue endovascular procedures are not performed because of a lack of randomized trial data, these patients may be recruited into randomized controlled trials testing endovascular procedures or other add-on experimental treatments. Naturally, not all patients with high DRAGON scores would be suitable candidates for endovascular procedures (eg, a patient >80 years with extensive early infarction, high glucose, previous disability, and late presentation). Hence, institutional inclusion criteria for endovascular approach have to be considered in individual cases after obtaining informed consent from patients or their caregivers. Finally, because thrombolysis treatment has a risk of intracranial hemorrhage that can influence patient outcome, 11 the final decision can be based both on the DRAGON score (predicting functional outcome) and a score predicting risk of symptomatic intracranial hemorrhage after IVT (eg, the SEDAN score). 12 There are some limitations of this study. The datasets include mostly white patients. Also, assessments of early ischemic changes on pretreatment CT (eg, posterior circulation ASPECTS score) 13 and the role of hyperdense signs in the basilar artery or posterior cerebral artery are warranted. The strength of the study is the large number of included patients. Furthermore, baseline characteristics and the outcome distribution in our dataset were similar to those of the Safe Implementation of Thrombolysis registry, 14 with somewhat different baseline National Institutes of Health Stroke Scale scores (median, 10 in our database and 12 in the SITS database).
In conclusion, the DRAGON score provides an accurate and immediate estimation of functional outcome in IVTtreated ischemic stroke patients. Validation in a large multicenter cohort and in prespecified subgroups confirms its generalizability.
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